Immunotherapeutic Compounds
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
72
NCT05659953
LMT503 First-in-human SAD, MAD, and FE Study
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 1, 2025
Completion: Mar 1, 2026
Loading map...